Featured Research

from universities, journals, and other organizations

How cancer cells protect themselves from low levels of oxygen

Date:
December 20, 2009
Source:
Journal of Clinical Investigation
Summary:
Not all regions of a tumor are equal in terms of their oxygen levels. One clinically important implication of this is that tumors with large areas with low levels of oxygen (areas known as hypoxic regions) are associated with poor prognosis and treatment response. Researchers have determined that a cellular response pathway known as the unfolded protein response pathway helps protect human tumor cells from hypoxia and anticancer irradiation treatment.

Not all regions of a tumor are equal in terms of their oxygen levels. One clinically important implication of this is that tumors with large areas with low levels of oxygen (areas known as hypoxic regions) are associated with poor prognosis and treatment response.

A team of researchers, led by Bradly Wouters, at the University of Toronto, Canada, has determined that a cellular response pathway known as the unfolded protein response pathway helps protect human tumor cells from hypoxia and anticancer irradiation treatment.

Further analysis indicated that the unfolded response pathway increased expression of two proteins involved in a cellular process known as autophagy, which is known to act to protect cells in times of stress.

Importantly, inhibition of autophagy sensitized cultured human tumor cells to hypoxia and sensitized human tumors xenografted into mice to irradiation, leading the authors to suggest that targeting the molecules they identified as important might be of clinical benefit.

The research is reported in the Journal of Clinical Investigation.



Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kasper M.a. Rouschop, Twan Van Den Beucken, Ludwig Dubois, Hanneke Niessen, Johan Bussink, Kim Savelkouls, Tom Keulers, Hilda Mujcic, Willy Landuyt, Jan Willem Voncken, Philippe Lambin, Albert J. Van Der Kogel, Marianne Koritzinsky, and Bradly G. Wouters. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. Journal of Clinical Investigation, 2009; DOI: 10.1172/JCI40027

Cite This Page:

Journal of Clinical Investigation. "How cancer cells protect themselves from low levels of oxygen." ScienceDaily. ScienceDaily, 20 December 2009. <www.sciencedaily.com/releases/2009/12/091214220146.htm>.
Journal of Clinical Investigation. (2009, December 20). How cancer cells protect themselves from low levels of oxygen. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/12/091214220146.htm
Journal of Clinical Investigation. "How cancer cells protect themselves from low levels of oxygen." ScienceDaily. www.sciencedaily.com/releases/2009/12/091214220146.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins